Royal Bank of Canada
MLYS icon

Royal Bank of Canada’s Mineralys Therapeutics MLYS Stock Holding History

Royal Bank of Canada’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
15,413
+15,261
+10,040% +$419K ﹤0.01% 4508
2026
Q1 		$4K Sell
152
-1,377
-90% -$40.4K ﹤0.01% 6503
2025
Q4 		$56K Buy
1,529
+1,107
+262% +$44.4K ﹤0.01% 5495
2025
Q3 		$16K Sell
422
-9,141
-96% -$198K ﹤0.01% 6311
2025
Q2 		$130K Buy
9,563
+8,264
+636% +$120K ﹤0.01% 5460
2025
Q1 		$21K Sell
1,299
-2,236
-63% -$25.7K ﹤0.01% 5909
2024
Q4 		$43K Buy
3,535
+661
+23% +$8.64K ﹤0.01% 5766
2024
Q3 		$34K Buy
2,874
+179
+7% +$2.17K ﹤0.01% 5868
2024
Q2 		$31K Buy
2,695
+2,251
+507% +$28.4K ﹤0.01% 5872
2024
Q1 		$6K Sell
444
-5,961
-93% -$73.6K ﹤0.01% 6387
2023
Q4 		$55K Buy
6,405
+4,213
+192% +$33.1K ﹤0.01% 5938
2023
Q3 		$21K Buy
2,192
+887
+68% +$11.6K ﹤0.01% 6167
2023
Q2 		$22K Buy
1,305
+411
+46% +$6.14K ﹤0.01% 6168
2023
Q1 		$14K Buy
+894
New +$15K ﹤0.01% 6173

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Royal Bank of Canada's MLYS Position: Q2 2026 in Review

Royal Bank of Canada increased its Mineralys Therapeutics (MLYS) stake by 10,040% in Q2 2026, buying an estimated $419K and bringing the position to 15,413 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #4508.

Royal Bank of Canada first reported a position in MLYS in Q1 2023 and has held it in 14 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Royal Bank of Canada held 15,413 shares of Mineralys Therapeutics worth $416K as of Q2 2026.
  • Royal Bank of Canada bought 15,261 Mineralys Therapeutics shares in Q2 2026, an estimated $419K.
  • Mineralys Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4508 holding.
  • Royal Bank of Canada first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.